FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes its activation in response to DNA damage

Oncogene

Volumn 33, Issue 47, 2014, Pages 5424-5433

  Yan, S ^a   Qiu, L ^a   Ma, K ^a   Zhang, X ^a   Zhao, Y ^a   Zhang, J ^a   Li, X ^a   Hao, X ^a   Li, Z ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

DNA damage; FATS; Mdm2; p53; ubiquitin linkage

Indexed keywords

C10ORF90 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; MDM2 PROTEIN, HUMAN; PROTEIN MDM2; PROTEIN P53;

CELL LINE; DNA DAMAGE; GENETICS; HUMAN; METABOLISM; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; UBIQUITINATION;

CELL LINE; CYTOSKELETAL PROTEINS; DNA DAMAGE; HUMANS; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84887560547     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.494     Document Type: Article

References (39)

1. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009; 10: 398-409.
2. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006; 22: 159-180.
3. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007; 315: 201-205.
4. Ulrich HD, Walden H. Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Boil 2010; 11: 479-489.
5. Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 2004; 8: 610-616.
6. Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009; 137: 133-145.
7. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17: 86-92.
8. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
9. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
10. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
11. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by Mdm2. Cell 1997; 91: 325-334.
12. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-6245.
13. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-626.
14. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429: 86-92.
15. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112: 779-791.
16. Wu X, Bayle JH, Olson D, Levine AJ. The p53-Mdm2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1132.
17. Jain AK, Barton MC. Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther 2010; 10: 665-672.
18. Migliorini D, Bogaerts S, Defever D, Vyas R, Denecker G, Radaelli E et al. COP1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest 2011; 121: 1329-1343.
19. Jung YS, Hakem A, Hakem R, Chen X. Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis. Mol Cell Biol 2011; 31: 3997-4006.
20. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006; 127: 775-788.
21. Durkin SG, Glover TW. Chromosome fragile sites. Annu Rev Genet 2007; 41: 169-192.
22. Ma K, Qiu L, Mrasek K, Zhang J, Liehr T, Quintana LG et al. Common fragile sites: genomic hotspots of DNA damage and carcinogenesis. Int J Mol Sci 2012; 13: 11974-11999.
23. Li Z, Zhang Q, Mao JH, Weise A, Mrasek K, Fan X et al. An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. Oncogene 2010; 29: 2659-2671.
24. Zhang X, Zhang Q, Zhang J, Qiu L, Yan S, Feng J et al. FATS is a transcriptional target of p53 and associated with antitumor activity. Mol Cancer 2010; 9: 244.
25. Zhang J, Gu L, Zhao L, Zhang X, Qiu L, Li Z. Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer. Chin Med J 2011; 124: 2894-2898.
26. Tian Y, Zhang J, Yan S, Qiu L, Li Z. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer. Lung Cancer 2012; 76: 416-422.
27. Mao JH, Li J, Jiang T, Li Q, Wu D, Perez-Losada J et al. Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice. Oncogene 2005; 24: 7924-7934.
28. Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC et al. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem 2004; 279: 42169-42181.
29. Wenzel DM, Lissounov A, Brzovic PS, Klevit RE. UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 2011; 474: 105-108.
30. Laine A, Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007; 26: 1477-1483.
31. Laine A, Topisirovic I, Zhai D, Reed JC, Borden KL, Ronai Z. Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 2006; 26: 8901-8913.
32. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
33. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 2009; 10: 755-764.
34. Hurley JH, Lee S, Prag G. Ubiquitin-binding domains. Biochem J 2006; 399: 361-372.
35. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-mediated apoptosis in glioblastoma. Cancer Discov 2012; 2: 140-155.
36. Brzovic PS, Lissounov A, Christensen DE, Hoyt DW, Klevit REA. UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination. Mol Cell 2006; 21: 873-880.
37. Wu H, Pomeroy SL, Ferreira M, Teider N, Mariani J, Nakayama KI et al. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med 2011; 17: 347-355.
38. Najafi SM, Li Z, Makino K, Shao R, Hung MC. The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. Biochem Biophys Res Commun 2003; 305: 1099-1104.
39. Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004; 64: 9080-9085.